REGENERON PHARMACEUTICALS, INC.
The article says demand for GLP-1 drugs is rising as approvals expand beyond diabetes to obesity and obstructive sleep apnea. It highlights Amgen (AMGN) with 27% YTD stock gains, Q2 revenue of $10.1B (+10% YoY) and adjusted EPS of $6.29, plus phase 3 MariTide. It also cites Regeneron (REGN) Q2 revenue $4.3B (+17%) and adjusted EPS $14.29, with phase 3 olatorepatide weight loss up to 19% in China.
Biohaven (BHVN) said it signed a clinical supply agreement with Regeneron (REGN) to test BHV-1530 with Regeneron’s cemiplimab (Libtayo) in solid tumors. The article also cites Regeneron Q2 2026 results: $4.3B revenue (+17% YoY), GAAP net income $1.29B, and Biohaven Q2 2026 net loss $137.3M.
A retrospective Medicare study of steroid-refractory polymyalgia rheumatica (415 matched pairs) found IL-6 receptor inhibitors tocilizumab or sarilumab plus glucocorticoids led more patients to discontinue or minimize glucocorticoids by year 1 versus csIM therapies (HR 1.28, P=.031/.025) and versus methotrexate (P=.11/.022). Safety was similar except higher hospitalized infections in year 1.
Over the past 7 days, alphai's AI scored 7 news stories mentioning REGN (REGENERON PHARMACEUTICALS, INC.). Coverage has been balanced: 2 bullish, 3 neutral, and 2 bearish.
Recent REGN coverage spans sector analysis, technology and financial news.
In the last 30 days, REGN insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($960K). The most active reporter was Guarini Kathryn with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
REGN gets a positive framing from Q2 growth and specific phase 3 efficacy figures for olatorepatide.
This is a partnership-driven pipeline support story for Libtayo, but it is not a new approval or efficacy datapoint in the text.
Indirect read-through only: funding disclosure does not confirm tocilizumab/sarilumab efficacy for REGN’s commercial pipeline.
This is an insider selling disclosure, not a fundamental company update. It may slightly affect sentiment but is unlikely to change near-term valuation on its own.
Regeneron is actively diversifying manufacturing pathways for Eylea HD to reduce dependency on the troubled Indiana facility.
alphai scores every news story that mentions REGN with an AI model for sentiment and relevance, and aggregates insider trades from REGENERON PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The article says demand for GLP-1 drugs is rising as approvals expand beyond diabetes to obesity and obstructive sleep apnea. It highlights Amgen (AMGN) with 27% YTD stock gains, Q2 revenue of $10.1B (+10% YoY) and adjusted EPS of $6.29, plus phase 3 MariTide. It also cites Regeneron (REGN) Q2 revenue $4.3B (+17%) and adjusted EPS $14.29, with phase 3 olatorepatide weight loss up to 19% in China.
6 min readBiohaven (BHVN) said it signed a clinical supply agreement with Regeneron (REGN) to test BHV-1530 with Regeneron’s cemiplimab (Libtayo) in solid tumors. The article also cites Regeneron Q2 2026 results: $4.3B revenue (+17% YoY), GAAP net income $1.29B, and Biohaven Q2 2026 net loss $137.3M.
6 min readA retrospective Medicare study of steroid-refractory polymyalgia rheumatica (415 matched pairs) found IL-6 receptor inhibitors tocilizumab or sarilumab plus glucocorticoids led more patients to discontinue or minimize glucocorticoids by year 1 versus csIM therapies (HR 1.28, P=.031/.025) and versus methotrexate (P=.11/.022). Safety was similar except higher hospitalized infections in year 1.
6 min readZoghbi Huda Y sold 800 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at $800.00 ($0.64M total) on 2026-08-10 under a Rule 10b5-1 trading plan.
1 min readScholar Rock removed Novo Nordisk’s ex-Catalent Indiana manufacturing site from its FDA submission for apitegromab after an FDA inspection classified the plant as “Official Action Indicated.” Scholar Rock will rely on an alternative U.S. fill-finish facility; the PDUFA action date remains Sept. 30, 2026. The Catalent site also affected Incyte’s Zynyz FDA bid.
6 min readAccording to CloudSEK Threat Intelligence, the Team PCP threat actor compromised LiteLLM in March 2026, exposing reconstructed data for 2,500+ organizations and about 434,000 CI/CD pipelines. CloudSEK says the FBI’s July 2026 FLASH advisory warns credentials may be weaponized later. Reported high-confidence victims include NVIDIA, AWS, Samsung, Salesforce, Cisco, and ServiceNow.
6 min readA roundup of Q2 earnings trends for major pharma and biotech firms highlights GLP-1 marketing spend, biosimilar and generic competition, and China-related risks. Eli Lilly raised Q2 marketing expenses 25% to $3.43B and lifted year-end revenue guidance to $85B-$87B. Novo Nordisk reported 5M Wegovy pill prescriptions in 30 weeks. Pfizer cut promotional costs and plans $2.5B savings (2027-29).
7 min readA phase 4 global registry of 691 adults with chronic rhinosinusitis with nasal polyps found that dupilumab improved nasal congestion, smell and Sino-Nasal Outcome Test scores, with benefits sustained through 24 months. Adverse events occurred in 23.9% of patients, with no new safety signals. Sponsored by Regeneron and Sanofi; published July 27 in Annals of Allergy, Asthma & Immunology.
5 min readThe article highlights three biotech stocks for August and later catalysts. Regeneron (REGN) is cited as down about 11% YTD despite Q1 2026 revenue of $3.605B and non-GAAP EPS $9.47, plus a $3.0B buyback. Moderna (MRNA) is noted for a Q1 2026 revenue jump to $389M and an Aug. 5 FDA PDUFA for flu vaccine mRNA-1010. Viking Therapeutics (VKTX) is pre-revenue with Phase 3 obesity trials and a $92.58 analyst target.
7 min readRegeneron (REGN) reported Q2 2026 revenue of $4.29B vs $3.82B Street estimate, with adjusted EPS $14.29 vs $10.21. EBIT was $1.65B vs $1.19B estimate, and EBIT margin rose to 38.53%. CFO said Regeneron fully repaid a Sanofi development balance, and collaboration revenue should step up in Q3. Dupixent sales grew 38% constant currency; EYLEA HD first outsold EYLEA in the U.S.
6 min read
